Clinical Trial Update: Safety, Tolerability, and Antiviral Activity of ANA598 in Patients With Genotype-1 Chronic HCV Infection [Phase 1]

View source ↗

Summary

Phase 1 study assessing safety, tolerability, and antiviral activity of ANA598 in patients with genotype-1 chronic hepatitis C.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• ANA598 (ANA598)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Chronic Hepatitis C | Phase 1 | Status: COMPLETED